Synthetic sulfoglycolipids targeting the serine–threonine protein kinase Akt

Bioorganic & Medicinal Chemistry
2016.0

Abstract

The serine-threonine protein kinase Akt, also known as protein kinase B, is a key component of the phosphoinositide 3-kinase (PI3K)-Akt-mTOR axis. Deregulated activation of this pathway is frequent in human tumors and Akt-dependent signaling appears to be critical in cell survival. PI3K activation generates 3-phosphorylated phosphatidylinositols that bind Akt pleckstrin homology (PH) domain. The blockage of Akt PH domain/phosphoinositides interaction represents a promising approach to interfere with the oncogenic potential of over-activated Akt. In the present study, phosphatidyl inositol mimics based on a β-glucoside scaffold have been synthesized as Akt inhibitors. The compounds possessed one or two lipophilic moieties of different length at the anomeric position of glucose, and an acidic or basic group at C-6. Docking studies, ELISA Akt inhibition assays, and cellular assays on different cell models highlighted 1-O-octadecanoyl-2-O-β-d-sulfoquinovopyranosyl-sn-glycerol as the best Akt inhibitor among the synthesized compounds, which could be considered as a lead for further optimization in the design of Akt inhibitors.

Knowledge Graph

Similar Paper

Synthetic sulfoglycolipids targeting the serine–threonine protein kinase Akt
Bioorganic & Medicinal Chemistry 2016.0
Development of sulfonamide AKT PH domain inhibitors
Bioorganic & Medicinal Chemistry 2011.0
Synthesis and structure–activity relationship of 3,4′-bispyridinylethylenes: Discovery of a potent 3-isoquinolinylpyridine inhibitor of protein kinase B (PKB/Akt) for the treatment of cancer
Bioorganic & Medicinal Chemistry Letters 2006.0
Biological evaluation and docking studies of recently identified inhibitors of phosphoinositide-3-kinases
Bioorganic & Medicinal Chemistry Letters 2012.0
Discovery and SAR of oxindole–pyridine-based protein kinase B/Akt inhibitors for treating cancers
Bioorganic & Medicinal Chemistry Letters 2006.0
Discovery of trans-3,4′-bispyridinylethylenes as potent and novel inhibitors of protein kinase B (PKB/Akt) for the treatment of cancer: Synthesis and biological evaluation
Bioorganic & Medicinal Chemistry Letters 2006.0
Design and synthesis of novel furoquinoline based inhibitors of multiple targets in the PI3K/Akt-mTOR pathway
Bioorganic & Medicinal Chemistry Letters 2008.0
Identification of a novel 3,5-disubstituted pyridine as a potent, selective, and orally active inhibitor of Akt1 kinase
Bioorganic & Medicinal Chemistry Letters 2006.0
Design of Selective, ATP-Competitive Inhibitors of Akt
Journal of Medicinal Chemistry 2010.0
Design, synthesis and biological evaluation of AKT inhibitors bearing a piperidin-4-yl appendant
MedChemComm 2018.0